

INDEX

- Abortion**
spontaneous
immune system in, 532
in lupus erythematosus, 550-551
in myasthenia gravis, 596
therapeutic, in lupus erythematosus, 549-550
- Acetaminophen in pregnancy, in autoimmune diseases, 637**
- Adenosis, vaginal, and postmenopausal bleeding, 775**
- Adolescence, menstrual disorders in, 690-700**
- Adrenal gland**
congenital hyperplasia of, menarchal delay in, 693
disorders with amenorrhea, 754-755
- Aging, and menstruation changes, 762**
- Amenorrhea, 749-757**
in adolescence, 690-700
adrenal causes of, 754-755
differential diagnosis of, 749-755
evaluation of, 755-756
in exercise and sports, 732-733, 750, 751
in hyperprolactinemia, 740-741
hypothalamic causes of, 749-751
ovarian causes of, 753-754
pituitary causes of, 752-753
psychologic aspects of, 733, 751, 780
thyroid causes of, 755
treatment of, 756-757
uterine causes of, 754
in weight loss, 732, 750
- Anemia, in rheumatoid arthritis, 566**
- Anesthesia, in myasthenia gravis in pregnancy, 597-598**
- Anorexia nervosa, amenorrhea in, 751**
- Anovulation, in hyperprolactinemia, 741-742**
- Anticholinesterase drugs, in myasthenia gravis, 598-600**
- Arthritis**
in lupus erythematosus, 548
rheumatoid, 558-575. *See also* Rheumatoid arthritis in pregnancy, 567-575
- Asherman's syndrome, 754**
treatment of, 757
- Aspirin in pregnancy**
in autoimmune diseases, 635-637
in rheumatoid arthritis, 569-570
- Autoimmune disease in pregnancy, drug therapy in, 635-639**
- Azathioprine in pregnancy**
in autoimmune diseases, 639
in lupus erythematosus, 554
in rheumatoid arthritis, 572-573
- Blistering diseases, subepidermal, in pregnancy, 605-612**
- Blood volume in pregnancy, 522-523**
- Bromocriptine**
in hyperprolactinemia, 742, 745-746
in premenstrual syndrome, 713
- Caplan's syndrome, 564**
- Catecholestrogens, and gonadotropin secretion, 675-676**
- Cervix uteri**
erosions in, and postmenopausal bleeding, 774
polyps of, 771-773
- Cesarean section, in immune thrombocytopenic purpura, 541-542**
- Chloroquine in pregnancy**
in autoimmune diseases, 639
in rheumatoid arthritis, 572
- Chorionic gonadotropin, 526**
and luteal rescue in fertile cycle, 665-666
- Chromosome abnormalities, in ovarian failure syndromes, 694-695**
- Complement levels, in lupus erythematosus in pregnancy, 552-553**
- Contraception, in lupus erythematosus, 554**
- Contraceptives, oral**
in dysmenorrhea, 722-723
in premenstrual syndrome, 712
- Corpus luteum, 660-667**
of pregnancy, 666
- Corticosteroid therapy in pregnancy**
in autoimmune diseases, 638-639
in herpes gestationis, 612
in immune thrombocytopenic purpura, 543
in lupus erythematosus, 553
in myasthenia gravis, 599
in polyarteritis nodosa, 585
in rheumatoid arthritis, 573-574

- Craniopharyngioma
 amenorrhea in, 752
 menarchal delay in, 694
- Cushing's syndrome
 amenorrhea in, 754-755
 menarchal delay in, 693
- Cyclophosphamide in pregnancy
 in polyarteritis nodosa, 585
 in rheumatoid arthritis, 572-573
- Dermatitis herpetiformis in pregnancy, 606
- Dilatation and curettage, in abnormal bleeding, 704-705
- Diuretics, in premenstrual syndrome, 711-712
- Dopamine
 effects in menstrual cycle, 780-781
 and prolactin secretion, 673, 736
- Dysmenorrhea, 719-727
 biologic mechanisms in, 720-722
 clinical features of, 719-720
 diagnosis of, 720
 primary, 719-725
 management of, 722-725
 prostaglandin production in, 721-722, 725
 secondary, 725-726
 treatment of, 725-726
 vasopressin secretion in, 781
- Endometrial hyperplasia, and postmenopausal bleeding, 773-774
- Endorphins
 and gonadotropin secretion, 674-675, 713-715
 and menstrual dysfunction, 781
 and premenstrual syndrome, 713-715
- Epstein-Barr virus, and rheumatoid arthritis, 563
- Erythema multiforme in pregnancy, 606
- Estrogen
 and gonadotropin secretion, 669-670
 luteolytic action of, 663-665
 ovarian production of, 648-650
- Exercise, and menstrual dysfunction, 728-734, 750-751
- Family planning, in lupus erythematosus, 554-555
- Fertility
 dysfunctional uterine bleeding affecting, 707-708
 in lupus erythematosus, 550
- α -Fetoprotein, 552-556
- Fetus
 in immune regulation of pregnancy, 531
 thyroid function assessment in, 626-627
- Fibroids, uterine, and postmenopausal bleeding, 773
- Flufenamic acid, in dysmenorrhea, 724
- Follicle-stimulating hormone
 and ovarian estrogen production, 648-650
 secretion in different forms, 672
- Follicular development, ovarian, hormonal control of, 648-659
- Galactorrhea, in hyperprolactinemia, 740-741
- Gold therapy in pregnancy
 in autoimmune diseases, 639
 in rheumatoid arthritis, 570-571
- Gonadotropin
 chorionic, 526
 and luteal rescue in fertile cycle, 665-666
 pituitary
 endorphins affecting secretion of, 672-673, 712-713
 neuroendocrine control of secretion of, 667-677
 releasing hormone, 667-669
 inhibition of, and amenorrhea, 749-750
- Graves' disease in pregnancy, 615-633
 diagnosis of, 619-621
 and evaluation of newborn, 628-631
 labor and delivery in, 627-628
 and long-term outcome of children, 631-632
 and maternal-fetal thyroid relationship, 615-617
 pathogenesis of, 617-619
 propylthiouracil in, 621-623
 radioiodine in, 623-625
 surgery in, 625-626
- Herpes gestationis, 605-612
 autoimmune factors in, 610-611
 clinical features of, 606-607
 fetal involvement in, 611-612
 histology of, 607-608
 hormonal factors in, 610
 lesion production in, 608-610
 treatment of, 612
- HLA antigen
 in Graves' disease, 617
 in herpes gestationis, 611
 in pregnancy, 530
 in rheumatoid arthritis, 562-563
- Hydroxychloroquine in pregnancy, in rheumatoid arthritis, 572
- Hyperthyroidism. *See* Graves' disease in pregnancy
- Hypoglycemia, premenstrual syndrome in, 712
- Hypogonadism
 hypergonadotropic, 694-695
 hypogonadotropic, 691-694
 irreversible, 693-694
 reversible, 692-693
- Hypothalamus
 diseases with hyperprolactinemia, 738
 dysfunction with amenorrhea, 749-752
 and gonadotropin secretion, 671
 maturational arrest in, 691-694
 irreversible, 693-694
 reversible, 692-693

- Hypothyroidism**
 hyperprolactinemia in, 739
 menarchal delay in, 693
- Ibuprofen**, in dysmenorrhea, 724
- Immune complex formation in pregnancy**, 528
- Immune system in pregnancy**, 521-533
 cellular immunity in, 528-532
 and drug therapy in autoimmune diseases, 635-639
 fetal regulation of, 531
 and Graves' disease, 615-633
 and herpes gestationis, 610-611
 humoral immunity in, 527-528
 impaired function of, 531-532
 and lupus erythematosus, 547-555
 and myasthenia gravis, 592-603
 and polyarteritis nodosa, 579-585
 and rheumatoid arthritis, 558-575
 and scleroderma, 587-591
- Immune thrombocytopenic purpura**, 537-544
- Immunoglobulin levels in pregnancy**, 527-528
- Immunosuppressive therapy in pregnancy**
 in autoimmune diseases, 639
 in lupus erythematosus, 554
 in polyarteritis nodosa, 585
 in rheumatoid arthritis, 572-573
- Indomethacin**
 in dysmenorrhea, 724
 in pregnancy, in autoimmune diseases, 637
- Infections in pregnancy**, immune function in, 532
- Infertility**, in dysfunctional uterine bleeding, 708
- Iodine**, radioactive, in Graves' disease in pregnancy, 623-625
- Kallmann's syndrome**
 amenorrhea in, 752
 menarchal delay in, 693
- Ketoprofen**, in dysmenorrhea, 724
- Labor and delivery**
 in Graves' disease, 627-628
 in lupus erythematosus, 553
 in myasthenia gravis, 597-598
 in rheumatoid arthritis, 575
 in thrombocytopenic purpura, immune, 541-543
- Lactogen**, placental, 526
- Lupus erythematosus in pregnancy**, 547-555
 diagnosis of, 547-549
 and effects of pregnancy termination, 549-550
 and family planning, 554-555
 fetoplacental effects of, 550-552
 management of, 552-554
 maternal effects of, 550
- Luteal phase of menstrual cycle**, 660-667
- Luteinizing hormone**
 receptors in corpus luteum, 663
 secretion in different forms, 672
 surge in menstrual cycle, 656, 658-659
- Luteolysis**, mechanisms in, 662-665
- Lymphocyte activity in pregnancy**, 528-530
- Mefenamic acid**, in dysmenorrhea, 724
- Menarche**, exercise affecting, 728-730
- Menopause**
 and benign postmenopausal bleeding, 769-776
 in atrophic vaginitis, 770-771
 in cervical erosions, 774
 in cervical polyps, 771-773
 in endometrial hyperplasia, 773-774
 in fibroids, 773
 in ovarian tumors, 774-775
 in pyometra, 775-776
 in vaginal adenosis, 775
 perimenopausal problems, 762
 diagnosis of, 766
 endocrine changes in, 762-764
 pathophysiology of, 764-766
 treatment of, 766-767
- Menstrual cycle**
 endocrine characteristics of, 647-677
 follicular development in, 648-659
 luteal phase in, 660-667
- Menstruation**
 and abnormal bleeding, 702-709
 and detection of ovulation, 705
 differential diagnosis of, 704
 dilatation and curettage in, 704-705
 in exercise and sports, 730-733
 history in, 702-704
 infertility in, 708
 organic causes of, 705
 pathologic bleeding in, 707-708
 physiologic bleeding in, 706-707
 postmenopausal, 769-776
 adolescent disorders in, 690-700
 anatomic abnormalities in, 695-696
 androgen sensitivity in, 696
 in eugonadal pubertal defects, 695
 evaluation and management of, 698-700
 in gonadal failure, 694-695
 in hypothalamic-pituitary maturation arrest, 691-694
 inappropriate positive feedback in, 696
 organic causes of, 697
 and amenorrhea, 749-757
 benign postmenopausal bleeding, 769-776
 dysmenorrhea, 719-726
 exercise affecting, 728-734, 750-751
 in hyperprolactinemia, 736-747

- Menstruation (*continued*)
 and perimenopausal problems, 762-767
 and premenstrual syndrome, 710-718
 psychosomatic aspects of dysfunction in, 733, 751, 777-782
- Myasthenia gravis, 592-603
 anticholinesterase drugs in, 598
 corticosteroids in, 598-599
 crisis in, 600
 diagnosis of, 592-593
 and drugs enhancing muscle weakness, 600-601
 immunopathology of, 593-594
 neonatal, 601-602
 plasmapheresis in, 599
 in pregnancy, 594-600
 analgesia and anesthesia in, 597-598
 thymectomy in, 599-600
- Naproxen sodium, in dysmenorrhea, 724
- Neostigmine, in myasthenia gravis, 598
- Neurotransmitters
 and menstrual cycle disorders, 780
 and secretion of gonadotropin releasing hormone, 672-674
- Oocyte maturation inhibitor, 658
- Ovarian follicles
 antral, 650-651
 dominant, selection of, 651-653
 feedback mechanisms affecting, 654-655
 hormonal control of development, 648-659
 luteal suppression of new growth in, 661-662
 preantral, 648-650
 preovulatory, 656-657
 primordial, 648
- Ovaries
 failure of
 amenorrhea in, 753-754
 competent, 695
 incompetent, 694-695
 polycystic syndrome of, amenorrhea in, 752
 tumors of, and postmenopausal bleeding, 774-775
- Ovulation, 657-659
 and anovulation in hyperprolactinemia, 741-742
 detection of, 705
 selection of dominant follicle in, 651-653
- Pemphigoid, bullous, in pregnancy, 606
- Penicillamine in pregnancy
 in rheumatoid arthritis, 572
 in scleroderma, 591
- Pituitary
 defects with amenorrhea, 752-753
 gonadotropin secretion, neuroendocrine control of, 667-677
 maturational arrest in, 691-694
 irreversible, 693-694
 reversible, 692-693
 tumors of, hyperprolactinemia in, 739
- Placental lactogen, 526
- Plasmapheresis
 in myasthenia gravis, 599
 in rheumatoid arthritis, 574
- Polyarteritis nodosa, 579-585
 clinical features of, 579-581
 cutaneous, 582
 diagnosis of, 581
 pathology of, 579
 in pregnancy, 582-585
 treatment of, 581-582
- Polyps, cervical, 771-773
- Pregnancy
 autoimmune diseases in, drug therapy in, 635-639
 blood volume in, 522-523
 Graves' disease in, 615-633
 herpes gestationis in, 605-612
 in hyperprolactinemia, 746-747
 immune system in, 521-533
 immune thrombocytopenic purpura in, 539-544
 lupus erythematosus in, 547-555
 myasthenia gravis in, 594-600
 plasma proteins in, 524-526
 polyarteritis nodosa in, 582-585
 prolactin levels in, 737
 rheumatoid arthritis in, 567-575
 scleroderma in, 589-591
- Premature labor
 in myasthenia gravis, 595-596
 in thrombocytopenic purpura, immune, 541
- Premenstrual syndrome, 710-718
 early identification of, 715
 and endogenous hormone allergy, 712
 endorphin activity in, 713-715
 in hypoglycemia, 712
 management of, 715-717
 progesterone insufficiency in, 710
 symptoms of, 709-710
 in vitamin B₆ deficiency, 712
- Progesterone
 and gonadotropin secretion, 670
 inhibiting follicular growth, 661-662
 insufficiency of, and premenstrual syndrome, 710
 and maternal immune response, 527
 as therapy in premenstrual syndrome, 716-717
- Prolactin
 biologic action of, 738
 and gonadotropin secretion, 673-674
 hyperprolactinemia, 736-747
 anovulation in, 741-742
 bromocriptine in, 743, 745-747

INDEX

- causes of, 738-740
 clinical features of, 740-741
 in disorders of inhibitory control, 738
 drug-induced, 740
 in endocrine-related disorders, 739-740
 evaluation of, 742-743
 in pituitary tumors, 739
 pregnancy in, 746-747
 stress-induced, 781-782
 surgery in, 743
 and luteal function, 666-667
 neuroregulation of, 736-737
 physiologic secretion of, 737-738
- Prolactinomas**, pubertal menstrual disorders in, 694
- Propylthiouracil**, in Graves' disease in pregnancy, 621-623
- Prostaglandin synthesis**
 in corpus luteum, 663
 in dysmenorrhea, 721-722, 725
- Prostaglandin synthetase inhibitors**, in dysmenorrhea, 723-724
- Proteins**, plasma, pregnancy-associated, 524-526
- Psychologic aspects of menstrual dysfunction**, 777-782
 in amenorrhea, 733, 751, 780
- Pubertal development**, abnormalities in, 691-696
- Purpura**, immune thrombocytopenic, 537-544
- Pyometra**, and postmenopausal bleeding, 775-776
- Pyridoxine**
 deficiency of, premenstrual syndrome in, 712
 as therapy in premenstrual syndrome, 716-717
- Radioiodine**, in Graves' disease in pregnancy, 623-625
- Rheumatoid arthritis**, 558-575
 autoimmune mechanisms in, 561
 clinical features of, 563-565
 criteria for diagnosis of, 559-560
 differential diagnosis of, 566-567
 Epstein-Barr virus in, 563
 genetic factors in, 562-563
 immunopathogenesis of, 560-561
 laboratory findings in, 566
 in pregnancy, 567-575
 chloroquine in, 571-572
 corticosteroids in, 573-574
 delivery in, 575
 gold therapy in, 570-571
 immunosuppressive therapy in, 572-573
 management of, 569-575
 nonsteroidal antiinflammatory agents in, 570
 penicillamine in, 572
 remissions in, 568-569
 salicylates in, 569-570
 radiology in, 565-566
 rheumatoid factors in, 561-562
- Salicylates in pregnancy**
 in autoimmune diseases, 635-637
 in rheumatoid arthritis, 569-570
- Scleroderma**, 587-591
 clinical features of, 587-588
 • diagnosis of, 588-589
 in pregnancy, 589-591
- Serotonin**, and prolactin release, 737
- Sexual development**, delayed, menstrual disorders in, 691-695
- Splenectomy in pregnancy**, in immune thrombocytopenic purpura, 541
- Sports**, and menstrual dysfunction, 728-734
- Stress**, and amenorrhea, 733, 751, 780
- Thrombocytopenic purpura**, immune, 537-544
 clinical features of, 538-539
 pathophysiology of, 537-538
 in pregnancy, 539-544
 delivery in, 541-543
 fetal and neonatal morbidity in, 541
 management of, 540-541, 543-544
 maternal morbidity in, 540
 treatment of, 539
- Thymectomy**, in myasthenia gravis, 599-600
- Thyroid disease**
 amenorrhea in, 755
 Graves' disease in pregnancy, 615-633
 hypothyroidism
 hyperprolactinemia in, 739
 menarchal delay in, 693
- Thyroidectomy**, in Graves' disease in pregnancy, 625-626
- Thyrotropin releasing hormone**, and prolactin secretion, 737
- Tolfenamic acid**, in dysmenorrhea, 724
- Turner's syndrome**, 694-695
- Uterus**
 cervical polyps, 771-773
 disorders with amenorrhea, 754
 endometrial hyperplasia, 773-774
 fibroids of, and postmenopausal bleeding, 773
- Vagina**, adenosis of, and postmenopausal bleeding, 775
- Vaginitis**, atrophic, 770-771
- Vasculitis**
 in polyarteritis nodosa, 579
 in rheumatoid arthritis, 565
- Vasopressin secretion**, stress affecting, 781
- Vitamin B₆ deficiency**, premenstrual syndrome in, 712
- Weight**, and menstrual disorders, 732, 750